Prodromal phase: Differences in prodromal symptoms, risk factors and markers of vulnerability in first episode mania versus first episode psychosis with onset in late adolescence or adulthood.

"CONFLICT OF INTEREST NV has received financial support for CME activities and travel funds from the following entities (unrelated to the present work): Angelini, Janssen, Lundbeck, Otsuka. MG has received grants and served as consultant or advisor for Ferrer, Lundbeck, and Janssen‐Cilag. MSV has received financial support for CME activities and travel funds from Janssen‐Cilag and Lundbeck, and reports no financial or other relationship relevant to the subject of this article. JARQ was on the speakers’ bureau and/or acted as consultant for Eli‐Lilly, Janssen‐Cilag, Novartis, Shire, Takeda, Bial, Shionogui, Lundbeck, Almirall, Braingaze, Sincrolab, Medice and Rubió, Raffo in the last 5 years. He also received travel awards (air tickets + hotel) for taking part in psychiatric meetings from Janssen‐Cilag, Rubió, Shire, Takeda, Shionogui, Bial, Medice and Eli‐Lilly. The Department of Psychiatry chaired by him received unrestricted educational and research support from the following companies in the last 5 years: Eli‐Lilly, Lundbeck, Janssen‐ Cilag, Actelion, Shire, Ferrer, Oryzon, Roche, Psious and Rubió. AMA has received funding for research projects and/or honoraria as a consultant or speaker for the following companies and institutions (work unrelated to the topic of this manuscript): Otsuka, Pfizer, AstraZeneca, Bristol‐Myers Squibb, Lundbeck, the Spanish Ministry of Economy and Competitiveness and Instituto de Salud Carlos III. MB has been a consultant for, received grant/ research support and honoraria from, and been on the speakers/advisory board of ABBiotics, Adamed, Angelini, Casen Recordati, Janssen‐Cilag, Menarini, Rovi and Takeda. EV has received grants and served as consultant, advisor or CME speaker for the following entities (unrelated to the present work): AB‐Biotics, Abbott, Allergan, Angelini, Dainippon Sumitomo Pharma, Ferrer, Gedeon Richter, Janssen, Lundbeck, Otsuka, Sage, Sanofi‐Aventis and Takeda. IP has received CME‐related honoraria or consulting fees from ADAMED, Janssen‐Cilag and Lundbeck. The rest of authors report no biomedical financial interests or potential conflicts of interest related to the present article."

"Funding information"